Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by jdstoxon Mar 14, 2019 11:00am
336 Views
Post# 29485177

RE:How much are they trying to raise?

RE:How much are they trying to raise?Digitel, no matter what company you talk about, you've always had a great time quoting various things that their people have said in interviews, on the website, in corporate presentations, financial reports, MD&As, etc. I understand that holding their feet to the fire about past predictions and actions is fair game, maybe even fun for you.

This business of ownership of shares by Bioasis board members and offficers does stick out. I have to deal with the question all the time. 

On January 9, 2019, Bioasis announced the appointment of Christine Antalik as Chief Financial Officer. In the press release it was also announced that our new CFO would receive options that would be priced "immediately following the expiry of the current 'blackout' period under the Company’s insider trading policy."

I don't know how long Bioasis has considered itself under blackout. Further, cautious executives and board members in all companies are free to impose their own blackouts when they think that legal prudence suggests they should.

You might consider for a moment the situation all corporate directors and executives are in when they're in possession of material or potentially material information that forces a blackout. If the information they're sitting on is bad, then I suppose they could feel relieved that they've been blacked out. But if the information is good, then their chance of buying cheap stock in financings or in the market may be forever gone. It's one of the reasons why many capable people refuse to be corporate insiders.

My point is, the company has publicly indicated that a blackout exists. It's intellectually lazy (or malicious) to complain about officer and director ownership of shares when a more relevant question might centre on possible reasons for the blackout. xB3, we do believe, may be something special. Is it so hard to contemplate that others in the industry might think the same?

jdstox

ps. Note in the PR referenced above that the fiscal year is described as September 30, 2018. As I'm sure you all know, the fiscal yearend is February 28, 2019, with reporting due by June 28, 2019.
.
.
Bullboard Posts